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Abstract 
The a-isoform of glycogen synthase kinase-3 (GSK3a) was inactivated by 80% towards a synthetic peptide substrate upon incubation with Mg-ATP 
and either MAP kinase-activated protein (MAPKAP) kinase-1 or p70 S6 kinase. Inactivation by either kinase resulted from the phosphorylation 
of Ser-21 and was reversed by treatment with protein phosphatase 2A,. Phosphorylation also decreased GSK3a activity towards glycogen synthase, 
inhibitor-2 and c-jun. The specificity of GSK3a was similar to GSK3/?, but with the synthetic peptide substrate heparin stimulated the 
dephosphorylated form of GSK3a (6-fold) more than GSK3/3 (1 .&fold). After phosphorylation, both isoforms were stimulated 15-20-fold by heparin. 
Kqv words: MAP kinase; Ribosomal S6 kinase; Glycogen synthase kinase-3; Growth factor; Insulin 
1. Introduction 
Glycogen synthase kinase-3 (GSK3) was identified as 
an inactivator of glycogen synthase in skeletal muscle [I], 
and subsequently shown to phosphorylate many other 
proteins in vitro including inhibitor-2 (a regulatory sub- 
unit of protein phosphatase-1) [2], the type-II regulatory 
subunit of cyclic AMP-dependent protein kinase [3], 
ATP-citrate lyase [4,5], eIF2B [6] (a nucleotide exchange 
factor required for the initiation of protein synthesis), 
tau (a microtubule-associated protein) [7] and the tran- 
scription factors c-jun and c-myc [8-IO]. Drosophila 
mutants lacking GSK3 are defective in several develop- 
mental processes, such as larval neurogenesis where it is 
implicated in a signal transduction pathway lying down- 
stream of a putative receptor protein, termed ‘notch’ 
[11,12]. 
Recently, evidence has been accumulating that GSK3 
is inhibited acutely by insulin. The activity of the ol- 
isoform of GSK3 (GSK3cc) decreased by about 50% 
upon stimulation of rat adipocytes with insulin [13], 
while the activity of the ,&isoform (GSK3/?) decreased by 
about 70% when Chinese hamster ovary cells that over- 
express the insulin receptor were stimulated with insulin 
[6]. In the latter case, inhibition was reversed by protein 
phosphatase 2A (PP2A), suggesting that insulin may 
promote serinejthreonine phosphorylation of GSK3/? [6]. 
*Corresponding author. Fax: (44) (382) 23-778. 
The first evidence that GSK3 activity is regulated by 
phosphorylation was obtained by Goode et al. [14], who 
reported that GSK3p was phosphorylated by protein 
kinase C (PK-C) in vitro decreasing its activity by about 
50%. However, these investigators reported that GSK3ol 
was not phosphorylated or inhibited by PK-C [ 141, indi- 
cating that this mechanism could not account for the 
inhibition of GSK3a: by insulin in adipocytes [5]. Re- 
cently, we reported that MAP kinase-activated protein 
kinase-1 (MAPKAP kinase-1, also termed RSK2 [15]) 
and p70 S6 kinase (~70~~~), which are both activated by 
insulin and other growth factors in vivo, phosphorylate 
GSK3/3 stoichiometrically at Ser-9 decreasing its activity 
by 95% [16]. These observations suggested that 
MAPKAP kinase-1 and/or p70S6K, which are compo- 
nents of distinct protein kinase cascades [17-l 91, may be 
involved in the regulation of GSK3/3 by extracellular 
agonists. However, in view of the reported failure of 
PK-C to phosphorylate GSK3cl [14], it was clearly es- 
sential to investigate whether the ol-isoform was also 
regulated by MAPKAP kinase-1 and/or p70S’jK. In this 
paper we establish that these protein kinases do indeed 
inactivate GSK3ol by phosphorylating Ser-21, the equiv- 
alent residue to Ser-9 of GSK3/?. 
2. Materials and methods 
2.1. Materials 
The trimeric form of protein phosphatase 2A, termed PP2A, (isolated 
by Dr. G. Moorhead as in [20]), glycogen synthase (isolated by Miss 
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F. Douglas as in [21]), MAPKAP kinase-1 1151 and GSK3/3 1161 were 
purified from rabbit skeletal muscle. Highly purified ~70’~” expressed 
in St9 cells was urovided bv Dr G. Thomas (Friedrich Miescher Insti- 
tute, Basel, Switzerland), bacterially expressed inhibitor-2 was provided 
by Dr A. DePaoli Roach, Indiana University School of Medicine, 
Indianapolis, USA) and bacterially expressed c-jun by Dr. E. Black and 
Dr. D. Gillespie (Beatson Cancer Institute, Glasgow, Scotland). Anti- 
bodies that recognise GSK3a and GSK3/3 were gifts from Dr. J. 
Woodgett, (Ontario Cancer Institute, Toronto, Canada) and the pro- 
tein kinase inhibitor H7 was from Professor H. Hidaka (Nagoya Uni- 
versity School of Medicine, Japan). Heparin from porcine intestinal 
mucosa (catalogue no. H3393) was purchased from Sigma Chemical 
Co. (Poole, Dorset, UK). 
2.2. Enzyme assays 
MAPKAP kinase-1 was assayed with a peptide related to the C- 
terminus of ribosomal protein S6 (30 PM) and ~70s~~ with the peptide 
RRRLSSLA (30 PM) as in [22]. GSK3 was assayed in an identical 
manner using the peptide YRRAAVPPSPSLSRHSSPHQSEDEEE 
(20 PM, provided by Dr M. Goedart, MRC Laboratory for Molecular 
Biology, Cambridge, UK) phosphorylated at its C-terminal serine with 
casein kinase 2 from rat liver (a gift from Professor L. Pinna, University 
of Padova, Italy) [16] to convert it to a substrate for GSK3. One unit 
of protein kinase activity (U) was that amount which catalysed the 
phosphorylation of I nmol of peptide substrate in 1 min. GSK3 was 
also assayed with 3 PM glycogen synthase, 3 PM c-jun and 3 PM 
inhibitor-2. Before assay, inhibitor-2 was converted to a much more 
effective substrate for GSK3 by phosphorylation with casein kinase-2; 
then heated at 100°C for 5 min to inactivate casein kinase-2. PPZA, was 
assayed as described [20] and one unit of activity was that amount 
which catalysed the dephosphorylation of 1 nmole of glycogen 
phosphotylase in 1 min. 
2.3. Inactivation and reactivation of GM3 
GSK3 (15 U/ml) was incubated in 20 mM MOPS (pH7.0), 0.01% (by 
vol.) Brij 35, 5% (by vol.) glycerol, 0.1% (by vol.) 2-mercaptoethanol 
(Buffer A), 10 mM Mg-acetate, 0.1 mM ATP, and either 3 U/ml 
MAPKAP kinase- 1 or 0.7 U/ml ~70s~~. At various times, aliquots were 
removed, diluted appropriately into ice-cold buffer containing 20 mM 
MOPS, pH 7.0, 1.0 mg/ml bovine serum albumin, 1 mM EDTA and 
0.1% (by vol.) /I-mercaptoethanol and assayed for GSK3 activity at a 
further S-fold dilution. 
2.4. Isolation of the tryptic peptide from G&Vu 
GSK3a (1 .O ml, 15 U/ml) was phosphorylated for 10 min with 
MAPKAP kinase-1 as described above, except that [y’*P]ATP (lo6 
cpm/nmol) replaced unlabelled ATP. The reaction was stopped by 
addition of Na-EDTA and NaF to final concentrations of 20 mM and 
50 mM, respectively, and the sample concentrated to 0.1 ml by centrif- 
ugation through a centricon 30 membrane (Amicon). The preparation 
was rediluted to 1 .O ml with buffer A plus 50 mM NaF and re-concen- 
trated, and this procedure repeated until free ATP comprised ~10% of 
the ‘*P-radioactivity. The native 32P-labelled GSK3a (0.3 ml) was then 
incubated for 20 min at 30°C with 0.3 ml of 0.2 mg/ml trypsin and the 
reaction terminated by addition of 0.2 ml of 20% (by mass) trichlo- 
roacetic acid. After standing on ice for 2 min, the suspensions were 
centrifuged for 5 min at 13,000 x g and the supematants, containing 
95% of the “P-radioactivity, chromatographed on a Vydac Cls column 
(Senarations Grouu, Hesoeria. CA. USA) eauilibrated in 0.1% (bv vol.) 
trithtoroacetic acid,.pH i.9. The &lumn was developed with ‘aiinear 
acetonitrile gradient with an increase in acetonitrile concentration of 
0.3% per min. Fractions of 0.4 ml were collected and 32P-radioactivity 
recorded with an on-line monitor. The major phosphopeptide was 
dried, resuspended in 0.1 ml of 0.1% (by vol.) acetic acid and added to 
0.1 ml of iron chelating Sepharose resin (Pharmacia) [23] equilibrated 
in 0.1% (by vol.) acetic acid. The resin was mixed end over end for 15 
min at room temperature, then centrifuged for 0.5 min at 14 000 x g, 
and the supematant discarded. The resin was washed 10 times with 0.4 
ml portions of 0.1% (by vol.) acetic acid and “P-radioactivity eluted 
with three 0.4 ml portions of water:ethanol:triethylamine, pH 10.5 
(9:9:2) followed by 0.4 ml of 0.1 M N-methylmorpholine acetate (pH 
8.0). The pooled eluates, containing 70% of the applied “P-radioactiv- 
ity, were dried and rechromatographed on the Cn column as described 
above, except hat trifluoroacetic acid was replaced by 10 mM ammo- 
nium acetate, pH 6.5. 
50.0*5 
A 
40 - 
z 
3 30- 
m 
z 
CJ 20- 
10 ;’ 
/ 
/ 
/ 
- o-4 
/ 
’ - 0.3 s 
0 
- 0.2 z” 
- 0.1 
C. Sutherland, I? CohenlFEBS Letters 338 (1994) 37-42 
3. Results 
3.1. Identification of GSk3a and separation from GSK3jCl 
The substrate specificity of GSK3 is unusual in that it 
phosphorylates SerIThr residues that lie N-terminal to 
another phosphoserine, the preferred consensus se- 
quence being Ser/Thr-Xaa-Xaa-Xaa-Ser(P) [24,25]. The 
substrate used to assay GSK3 routinely is a synthetic 
peptide, termed GS peptide- [16], which only becomes 
a substrate after its most C-terminal serine residue is 
phosphorylated by casein kinase-2 ([25,26] and Fig. 1A). 
Using this substrate, we recently purified GSK3/I 15,000- 
fold from rabbit skeletal muscle to a purity of 25% by a 
procedure involving successive chromatographies on 
CM-Sephadex, DEAE-cellulose, S-Sepharose and 
Mono-S. The major peak of GSK3 activity (GSK3/?) 
from S-Sepharose was preceded by a minor peak of ac- 
tivity that was also active towards GS peptide- provided 
0' 0 
10 20 30 40 
fraction number 
B 
kDa 
fraction 25 27 29 31 33 
Fig. 1. Separation of GSK3a and GSK3/? by chromatography on S- 
Sepharose. (A) GSK3 (450 U, 100 ml) from the DEAE-cellulose flow- 
through [16] was applied to the column equilibrated in 20 mM MOPS 
(pH 7.0), 1 mM EDTA, 0.01% (by vol.) Brij 35, 5% (by vol.) glycerol 
and 0.1% (by vol.) 2-mercaptoethanol. After washing with 50 ml of 
equilibration buffer, the column was developed with a 200 ml linear 
gradient to 0.4 M NaCl (broken line). Fractions (3 ml) were assayed 
for GSK3 activity in the absence (open circles) or presence (closed 
circles) of 0.1 mg/ml heparin usmg GS peptide- previously 
phosphorylated with casein kinase-2. The column was also assayed in 
the absence of heparin with GS peptide- not phosphorylated by casein 
kinase-2 (closed triangles). (B) Fractions from (A) were subjected to 
SDSlpolyacrylamide gel electrophoresis and immunoblotted with anti- 
bodies that recognise GSK3a (a, 51 kDa) and GSK3/I (/I. 47 kDa) [27]. 
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Fig. 2. Both isoforms of GSK3 are inactivated by MAPKAP kinase-I 
(A) and ~70s~~ (B) and reactivated by protein phosphatase 2A,. (A) 
GSK3o (triangles) or GSK3B (circles) (15 U/ml) were incubated with 
Mg-ATP in the presence (open symbols) and absence (closed symbols) 
of MAPKAP kinase-1 (3 U/ml). After 30 min, phosphorylation was 
stopped with excess Na-EDTA, and PP2A, added (final concentration, 
2 U/ml). The broken lines show experiments where okadaic acid (1 PM) 
was added together with PP2A,. GSK3 activity was measured with GS 
peptide- at the times indicated. (B) The experiment and symbols are 
as described in (A), except that MAPKAP kinase-1 was replaced by 
~70~~~ (0.7 U/ml). 
that it had been phosphorylated by casein kinase-2 
(Fig. 1A). Furthermore, this minor peak was stimulated 
5-fold to 6-fold by heparin (0.1 ,@ml), in contrast to 
GSK3/? whose activity was only increased slightly by this 
glycosaminoglycan (Fig. 1A). Immunoblotting of the 
fractions with an antibody that recognises GSK3a and 
GSK3/? revealed a cross-reacting species which co-eluted 
with the minor peak; its apparent molecular mass (51 
kDa) was identical to GSK3a [27] (Fig. 1B). The major 
peak cross-reacted with a 47 kDa species, the same mo- 
lecular mass as GSK3/I (Fig. 1B). 
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Fig. 3. Isolation and sequence analysis of the major tryptic 
phosphopeptide from GSK3a phosphorylated by MAPKAP kinase-1. 
(A) “P-1abelled GSK3a maximally phosphotylated by MAPKAP ki- 
nase-1 (section 2.3) was digested with trypsin and chromatographed on 
a C,, column at pH 1.9 (section 2.4). The full line shows the’*P-radio- 
activity and the broken line the acetonitrile gradient. (B) Identification 
of the residue in GSK3a phosphorylated by MAPKAP kinase-1. The 
major tryptic phosphopeptide from A was further purified (section 2.4) 
and 42 pmol (4,200 cpm) sequenced twice; firstly by conventional gas 
phase sequencing to identify amino acid residues, second by solid phase 
sequencing after coupling the peptide covalently to an arylamine mem- 
brane [22]. The figure shows “P-radioactivity released, and phenyl- 
thiohydantoin amino acid identified after each cycle of Edman degra- 
dation. The sequence corresponds to residues 19 to 27 of rat GSK3a 
although phenylthiohydantoin amino acids were identified unam- 
biguously up to residue 36. 
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3.2. Inactivation of GSK3a by MAPKAP kinase-1 and 
p70S6” 
The first half of the peak of GSK3a, which was free 
of GSK3& was pooled and further purified by chroma- 
tography on Mono-S as in [16]. When this preparation, 
which was estimated to be 510% pure, was incubated 
with Mg-ATP and either MAPKAP kinase-1 or ~70~~~ 
its activity decreased and reached a plateau at about 80% 
inhibition (Fig. 2). No inhibition occurred if MAPKAP 
kinase-1 and ~70~~~ were omitted. Under the same con- 
ditions the activity of GSK3/? was decreased by 95% 
(Fig. 2). GSK3a, like GSK3/?. could be fully reactivated 
by incubation with PP2A, (Fig. 2) and reactivation was 
prevented by the inclusion of okadaic acid, a PP2A in- 
hibitor (Fig. 2). GSK3a and GSK3P which had not been 
inactivated by phosphorylation were stimulated 20-30% 
and 4045%, respectively, upon incubation with PP2A,, 
indicating that the purified enzymes were partially 
phosphorylated. 
3.3. Identljication of the major residue on GSK3a 
phosphorylated by MAPKAP kinase-1 and ~70~~~ 
Incubation of GSK3a preparations with Mg- 
[Y-~‘P]ATP and MAPKAP kinase-1 resulted in the phos- 
phorylation of a single 51 kDa protein in the preparation 
(data not shown) and following tryptic digestion, chrom- 
atography on a C,, column at pH 1.9 revealed one major 
3’P-peptide luting at 14% acetonitrile (Fig. 3A). After 
further purification using an iron chelate column, which 
binds phosphopeptides relatively selectively [23]. and 
chromatography on the C,, column at pH 6.5, the 
phosphopeptide was pure and its N-terminal sequence 
(Thr-Ser-Ser-Phe-Ala-Glu-Pro-(Gly) ,0-Pro) corresponded to 
residues 19-36 of GSK3a. The site of phosphorylation 
was Ser-21 (Fig. 3B). Phosphorylation of GSK3a with 
p70= also labelled the 51 kDa band and tryptic diges- 
tion and chromatography on the C,* column yielded the 
C Suiherland, P Cohen1 FEBS Letters 338 (1994) 37-42 
same major phosphopeptide obtained after phosphoryla- 
tion with MAPKAP kinase-1 (data not shown). 
3.4. Effect of phosphoryiation on GSK3a and GSK3p 
activity 
When matched for activity towards GS peptide-2, 
GSK3a and GSK3B had similar relative activities to- 
ward glycogen synthase, inhibitor-2 and c-jun (Table 1). 
Phosphorylation of GSK3a decreased activity towards 
c-jun (70%) and inhibitor-2 (52%) somewhat less than 
activity towards GS peptide- (80%) (Table 1). When 
glycogen synthase was the substrate, the inhibitory effect 
of phosphorylation was more marked in the presence of 
0.15M KC1 (Fig. 4), as found previously for GSK3B [ 161. 
The effect of phosphorylation on activity also varied 
with the glycogen synthase preparation. For example in 
the absence of KCl, phosphorylation of GSK3@ had no 
effect on the rate of phosphorylation of one glycogen 
synthase preparation [I61 (Fig. 4B), but inhibited by 
50%, the rate of phosphorylation of another preparation 
prepared more recently. In the presence of KCI, the 
phosphorylated form of GSK3b (Fig. 4B) had a much 
lower activity than the dephosphorylated form with ei- 
ther glycogen synthase preparation. A similar result was 
obtained with GSK3a (data not shown). Glycogen syn- 
thase is known to aggregate on storage, which may affect 
its interaction with GSK3. 
The phosphorylated forms of GSK3a and GSK3/? 
were stimulated 15-fold to 20-fold by heparin when GS 
peptide- was the substrate and the effect of phospho- 
rylation on activity was therefore far less pronounced 
when this glycosaminoglycan was included in the assays. 
The heparin concentration required for half maximal 
activation of phosphorylated or dephosphorylated 
GSK3a and GSK3/? was 0.5-l pg/ml. With other sub- 
strates heparin had little effect on the activity of either 
GSK3 isoform (Table 1). 
Table 1 
Effect of phosphorylation and heparin on the activities of GSK3a and GSK3/? towards different substrates 
(a) Relative Activity (b) Effect of phosphorylation (c) Effect of heparin 
(inhibition %) (stimulation-fold) 
GSK3a-D GSK3/3-D GSK3a GSK3/? GSK3a-D GSK3a-P GSK3/3-D GSK3/Y-P 
GS peptide- (20 PM) 100 100 82 +_ 2 95 +_ 1 5.7 f 0.8 18.9 + 1 1.8 +_ 0.3 14.2 f 2 
Glycogen synthase (3 ,uM) 45 f 3 39 +2 63 f 5* 90 f 7* 1.1 + 0.1* 1.1 + 0.1* 1.1 It 0.2; 0.8 f O.l* 
Inhibitor-2 (3 PM) 6 +2 8.5 f 2 52 f 2 86 f 6 0.9 f 0.1 0.9 f 0.1 0.8 +_ 0.1 1.0 f 0.2 
c-jun (3 PM) 0.2 f 0.1 0.4 f 0.2 71 f 6 96 f 4 1.3 f 0.2 1.7 * 0.4 1.1 + 0.2 2.5 + 0.6 
GSK3a and GSK3/3 were maximally phosphorylated with MAPKAP kinase-I (section 2.3) and assayed with the substrates Indicated. The table shows 
(a) the activity of dephosphorylated GSK3a (GSK3a-D) and GSK3,B (GSK3,&D) towards glycogen synthase, Inhibitor-2 and c-jun relative to GS 
peptide-2; (b) the effect of phosphorylation on activity measured as % inhibition. and (c) the effect of heparin (0.1 mg/ml) on the activities of the 
dephosphorylated (D) and phosphorylated (P) forms of each GSK3 isoform. The protein kinase inhibitor H7 was included in assays with glycogen 
synthase to inactivate MAPKAP kinase-1 which phosphorylates this substrate. 
*0.15 M KC1 was present in these assays for reasons discussed in the text. Activities are given as S.E.M. for three different experiments (GS-peptide- 
and c-jun) or the average of two experiments (inhibitor-2 and glycogen synthase). 
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Fig. 4. Effect of phosphorylation by MAPKAP kinase-1 on the activity 
of GSK3 towards glycogen synthase at different concentrations of KCl. 
(A) The dephosphorylated forms of GSK3a (open triangles) and 
GSK38 (open circles) and the phosphorylated forms of GSK3& (closed 
triangles) and GSK3B (closed circles) were assayed with glycogen syn- 
thase (3 PM) at the KC1 concentrations indicated. (B) Dephosphory- 
lated GSK3B (circles) and phosphorylated GSK3B (triangles) were as- 
sayed with two different glycogen synthase preparations (open and 
closed symbols). 
4. Discussion 
In this paper we have demonstrated that GSK3& is 
phosphorylated at Ser-21 by MAPKAP kinase-I and 
p70s= in vitro and that phosphorylation is accompanied 
by the inhibition of activity. The sequence surrounding 
Ser-21 of GSK3a (RARTSSFAE) [271 is very similar to 
that surrounding Ser-9 of GSK3/3 (RPRTISFAE) [27] 
and Drosophila GSK3 (RPRTSSFAE) [28], indicating a 
striking conservation of this regulatory phosphorylation 
site. 
Although phosphorylation inhibited the GSK3a prep- 
arations somewhat less than the GSK3/? preparations 
41 
(Table l), this difference may be an in vitro artefact. We 
have found that after chromatography on S-Sepharose, 
GSK3a is gradually converted to a 48 kDa species that 
is recognised by GSK3 antibodies, but cannot be 
phosphorylated by either MAPKAP kinase-1 or ~70~~~. 
The 48 kDa species, which has been observed previously 
[27] may be a form of GSK3cx truncated at the N-termi- 
nus that cannot be inactivated by phosphorylation. 
A heparin-stimulated protein kinase was detected sev- 
eral years ago, whose substrate specificity was similar to 
GSK3, but which lost sensitivity to heparin after tryptic 
digestion [29]. This could be the dephosphorylated form 
of GSK3a or the phosphorylated form of GSK3ol and/or 
GSK3j?, since these species are stimulated by heparin 
considerably with GS peptide- as substrate (Fig. 1, 
Table 1). However, the heparin-stimulated protein ki- 
nase identified previously was assayed with glycogen 
synthase and neither of the GSK3 isoforms we purified 
were stimulated significantly by heparin with this sub- 
strate. The identity of the heparin-stimulated protein ki- 
nase therefore remains uncertain. 
It is clearly now critical to establish whether phospho- 
rylation of Ser-21 (GSK3a) and Ser-9 (GSK3/?) underlie 
the acute inhibition of these enzymes by insulin in rat 
adipocytes [5] and Chinese hamster ovary cells [6], and 
whether this regulatory mechanism operates in other 
cells following stimulation by growth factors and other 
agonists that activate ~70~~~ and the MAP kinase cas- 
cade. The identification of the inactivating phosphoryl- 
ation sites and the elution positions of each tryptic 
phosphopeptide during C,* chromatography reported in 
this paper and in [16] will greatly facilitate these investi- 
gations. 
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